[an error occurred while processing this directive] | [an error occurred while processing this directive]
Sulfasalazine increases the radiosensitivity of colorectal cancer cells by promoting ferroptosis
Li Meng1, Li Chan1, Chen Yao1, Pan Haixia2, Jin Tao1, Tian Shumei1, Zhao Gang3, Xie Ke2
1Department of Oncology, People's Hospital of Xinjin, Chengdu, Chengdu 611430, China; 2Department of Oncology, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, Chengdu 610031, China; 3Lab of Experimental Oncology, West China Hospital of Sichuan University, Chengdu 610041, China
AbstractObjective To investigate the radiosensitization effect of low‐dose sulfasalazine (SAS) on colorectal cancer (CRC) cells. Methods Proliferation inhibition effect of SAS on CRC cells was detected by CCK‐8 assay, and the concentration of SAS in vitro assays was based on its IC10 value. CRC cells were treated with SAS alone or combined with inhibitors of apoptosis, autophagy, ferroptosis and necroptosis, then cell viability was detected by CCK‐8 assay. Trypan blue staining, clone formation assay and cell growth curves were used to verify the radiosensitization effect of SAS on CRC cells in vitro. CRC cells were treated with SAS and radiotherapy, then the intracellular contents of lipid peroxidation and the protein levels of GPX4, PTGS2, cleaved PARP and active caspase 3 were evaluated, respectively. Subcutaneous xenograft tumor mouse model was established to further verify the radiosensitization effect of SAS in vivo. Results High dose (lethal dose) of SAS could induce apoptosis and ferroptosis in CRC cells. Low dose (non‐lethal dose) of SAS enhanced the radiosensitivity of CRC cells in vitro, and the radiosensitivity effect of SAS could only be abolished by ferroptosis inhibitor (Fer‐1). Low dose of SAS combined with radiotherapy significantly down‐regulated the expression of GPX4, whereas increased the intracellular lipid peroxidation levels and the expression of PTGS2. SAS also showed significant radiosensitization effect in subcutaneous xenograft tumor model. Conclusion Our findings suggest that low‐dose SAS could increase the radiosensitivity of CRC cells by promoting ferroptosis.
Fund:Medical research project of Chengdu Municipal Health Commission (2020189)
Corresponding Authors:
Xie Ke, Email: 292879981@qq. com
Cite this article:
Li Meng,Li Chan,Chen Yao et al. Sulfasalazine increases the radiosensitivity of colorectal cancer cells by promoting ferroptosis[J]. Chinese Journal of Radiation Oncology, 2022, 31(8): 727-731.
Li Meng,Li Chan,Chen Yao et al. Sulfasalazine increases the radiosensitivity of colorectal cancer cells by promoting ferroptosis[J]. Chinese Journal of Radiation Oncology, 2022, 31(8): 727-731.
[1] Siegel RL, Miller KD, Goding Sauer A, et al.Colorectal cancer statistics, 2020[J]. CA Cancer J Clin, 2020,70(3):145‐164.DOI: 10.3322/caac.21601. [2] Stockwell BR, Friedmann Angeli JP, Bayir H, et al.Ferroptosis: a regulated cell death nexus linking metabolism, redox biology,disease[J]. Cell, 2017,171(2):273‐285.DOI: 10.1016/j.cell.2017.09.021. [3] Lei G, Zhang Y, Koppula P, et al.The role of ferroptosis in ionizing radiation‐induced cell death and tumor suppression[J]. Cell Res, 2020,30(2):146‐162.DOI: 10.1038/s41422‐019‐0263‐3. [4] Yamaguchi Y, Kasukabe T, Kumakura S.Piperlongumine rapidly induces the death of human pancreatic cancer cells mainly through the induction of ferroptosis[J]. Int J Oncol, 2018,52(3):1011‐1022.DOI: 10.3892/ijo.2018.4259. [5] 喻浩宸,陈锐,郭世朋,等.柳氮磺吡啶诱导乳腺癌ZR‐75‐1细胞发生铁死亡及其机制研究[J]. 肿瘤, 2018,38(10):933‐941.DOI: 10.3781/j.issn.1000‐7431.2018.11.346. Yu HC, Chen R, Guo SP, et al.Sulfasalazine induces ferroptosis of breast cancer ZR‐75‐1 cells and its mechanism[J]. Tumor, 2018,38(10):933‐941.DOI: 10.3781/j.issn.1000‐7431.2018.11.346. [6] 季赢,陈维雄,陆允敏.青藤碱和柳氮磺吡啶对小鼠实验性结肠炎的作用和机制[J]. 中华消化杂志, 2014, 34(03):170‐174.DOI: 10.3760/cma.j.issn.0254‐1432.2014.03.007. Ji Y, Chen WX, Lu YM, et al.Role and mechanism of sinomenine and sulfasalazine in experimental colitis of mice model [J]. Chin J Dig, 2014,34(03):170‐174.DOI: 10.3760/cma.j.issn.0254‐1432.2014.03.007. [7] Friedmann Angeli JP, Krysko DV, Conrad M.Ferroptosis at the crossroads of cancer‐acquired drug resistance and immune evasion[J]. Nat Rev Cancer, 2019,19(7):405‐414.DOI: 10.1038/s41568‐019‐0149‐1. [8] Hassannia B, Vandenabeele P, Vanden Berghe T.Targeting ferroptosis to iron out cancer[J]. Cancer Cell, 2019,35(6):830‐849.DOI: 10.1016/j.ccell.2019.04.002. [9] Lei G, Mao C, Yan Y, et al.Ferroptosis, radiotherapy,combination therapeutic strategies[J]. Protein Cell, 2021,12(11):836‐857.DOI: 10.1007/s13238‐021‐00841‐y. [10] Chen X, Kang R, Kroemer G, et al.Broadening horizons: the role of ferroptosis in cancer[J]. Nat Rev Clin Oncol, 2021,18(5):280‐296.DOI: 10.1038/s41571‐020‐00462‐0. [11] Klotz U, Maier K, Fischer C, et al.Therapeutic efficacy of sulfasalazine and its metabolites in patients with ulcerative colitis and Crohn's disease[J]. N Engl J Med, 1980,303(26):1499‐1502.DOI: 10.1056/NEJM198012253032602. [12] Wahl C, Liptay S, Adler G, et al.Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B[J]. J Clin Invest, 1998,101(5):1163‐1174.DOI: 10.1172/JCI992. [13] Gout PW, Buckley AR, Simms CR, et al.Sulfasalazine, a potent suppressor of lymphoma growth by inhibition of the x(c)‐ cystine transporter: a new action for an old drug[J]. Leukemia, 2001,15(10):1633‐1640.DOI: 10.1038/sj.leu.2402238. [14] Dixon SJ, Lemberg KM, Lamprecht MR, et al.Ferroptosis: an iron‐dependent form of nonapoptotic cell death[J]. Cell, 2012,149(5):1060‐1072.DOI: 10.1016/j.cell.2012.03.042.
2022, Vol. 31 
